Myocarditis is an inflammatory disorder of cardiac muscles that is caused by toxic substances, immune system, infections and autoimmune disease. The infectious strains (bacteria or viruses) are generally responsible for the acute myocarditis in which subsequent disturbance of right or left ventricular function occurs. Myocarditis can be easily diagnosed by long-term electrocardiogram, computed tomography, magnetic resonance imaging, electrocardiography, and diagnostic catheterization. Myocarditis can be symptomatized by fatigue or listlessness, joint pain, leg swelling, rapid breathing, chest pain, rapid heart rate, fainting, and low urine output. Vycellix, Inc. is in the process of developing VY-OZ as an adjuvant therapy for dampening viral inflammation, for the treatment of myocarditis. Targeted Cell Therapies, LLC is also in the process of developing a drug candidate targeting monocyte chemoattractant protein-1 (MCP-1/CCL2), for the treatment of myocarditis. Some of the companies and universities having the pipeline of myocarditis include Targeted Cell Therapies, LLC, Vycellix, Inc., Stanford University, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.